Business Context and Reporting Period
Oncolytics Biotech Inc., a foreign private issuer based in Calgary, Alberta, Canada, filed this Form 6-K for the month of April 2004. The filing serves as a formal notice to the Toronto Stock Exchange regarding a corporate action approved by the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a stock option grant rather than a financial performance report.
Material Changes
The primary material event disclosed is the grant of stock options to purchase 50,000 common shares of the Corporation. The exercise price for these options is set at $9.38 per share, reflecting the closing price on the Toronto Stock Exchange on April 2, 2004. This grant is subject to regulatory approval and will be detailed further in the company's monthly report.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. No specific risks or contingencies are discussed in this text, other than the standard condition that the option grant is subject to regulatory approval.
Investor Verification Checklist
- Verify the final regulatory approval status of the 50,000 stock options granted.
- Confirm the exercise price of $9.38 per share against the April 2, 2004 closing price.
- Review the upcoming monthly report for a detailed outline of the grant activity and recipient details.
- Check subsequent filings for any dilution impact on existing shareholders.